SMi Reports: Alexion Pharmaceuticals and Minoryx Therapeutics to deliver presentations at the 9th Annual Orphan Drugs and Rare Diseases Conference The orphan drugs market recently saw an explosion of interest from pharmaceutical companies and biotechs, […]
US-based AbbVie has signed an agreement to acquire Irish pharmaceutical firm Allergan in a deal valued at around $63bn (£49.4bn). As per terms of the deal, Allergan shareholders will secure 0.8660 AbbVie shares and $120.30 […]
NantKwest announced that the company’s PD-L1 t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial in patients with locally advanced or metastatic solid […]
Rafael Pharmaceuticals, a leader in the growing field of cancer metabolism-based therapeutics, has entered into an out-licensing agreement with Ono Pharmaceutical, a pharmaceutical company committed to creating innovative medicines. The exclusive license agreement is for […]
Bristol Myers-Squibb (BMS) has announced that its blockbuster cancer drug Opdivo (nivolumab) has failed to reach its primary endpoint in the Phase III CheckMate-459 trial. This trial compared Opdivo with sorafenib, the current standard of […]